

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**Quanterix Corporation**

---

(Name of Issuer)

**Common Stock, par value \$0.001 per share**

---

(Title of Class of Securities)

**74766Q101**

---

(CUSIP Number)

**Patrick O'Malley**  
**DLA Piper LLP (US), 4365 Executive Drive, Suite 1100**  
**San Diego, CA, 92121**  
**(858) 677-1400**

---

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**01/09/2025**

---

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

**CUSIP No. 74766Q101**

Name of reporting person

1

Akoya Biosciences, Inc.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3 SEC use only  
Source of funds (See Instructions)

4  
OO  
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With: 8 0.00  
Shared Voting Power

9 2,955,532.00  
Sole Dispositive Power

10 0.00  
Shared Dispositive Power

11 Aggregate amount beneficially owned by each reporting person  
2,955,532.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13   
Percent of class represented by amount in Row (11)  
6.2 %

14 Type of Reporting Person (See Instructions)  
CO

## SCHEDULE 13D

### Item 1. Security and Issuer

Title of Class of Securities:

(a) Common Stock, par value \$0.001 per share

Name of Issuer:

(b) Quanterix Corporation

Address of Issuer's Principal Executive Offices:

(c) 900 Middlesex Turnpike, Billerica, MASSACHUSETTS , 01821.

### Item 2. Identity and Background

(a) Akoya Biosciences, Inc.

(b) 100 Campus Drive, 6th Floor, Marlborough, MA 01752

(c) Akoya is a biotechnology company. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy

(d) During the last five years, Akoya has not, and to the best of Akoya's knowledge, none of the persons listed on Schedule A attached hereto has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, Akoya has not, and to the best of Akoya's knowledge, none of the persons listed on Schedule A attached hereto has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future

violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws

(f) United States of America

Item 3. Source and Amount of Funds or Other Consideration

The Voting Agreement On January 9, 2025, in connection with the execution of the Merger Agreement (as defined below), the Reporting Persons entered into a voting agreement (the "Voting Agreement"), pursuant to which each Reporting Person has agreed, among other things, to vote or cause to be voted its respective shares of beneficially owned Common Stock (i) in favor of the issuance of shares by the Issuer as required in connection with the Merger (as defined below) and other required transactions contemplated by the Merger Agreement, and (ii) against (x) any action or agreement that would reasonably be expected to result in a breach of the Merger Agreement by the Issuer and (y) any competing transaction proposal, or any agreement, transaction or other corporate action that would reasonably be expected to, frustrate the purposes, or prevent or materially delay the consummation, of the transactions contemplated in the Merger Agreement. The agreement of the Reporting Persons other than Akoya Biosciences, Inc. to enter into the Voting Agreement was a condition and inducement to Akoya Biosciences, Inc. to enter into the Merger Agreement. The Merger Agreement On January 9, 2025, Akoya Biosciences, Inc. ("Akoya") entered into an Agreement and Plan of Merger (the "Merger Agreement") with the Issuer and Wellfleet Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Issuer ("Merger Sub"). The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Akoya (the "Merger"), with Akoya continuing as the surviving company and a wholly-owned subsidiary of the Issuer following the transaction. Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), and as a result of the Merger, each share of common stock of Akoya issued and outstanding immediately prior to the effective time of the Merger will be converted into the right to receive 0.318 shares of Common Stock of the Issuer (the "Exchange Ratio"). In addition, at the Effective Time and as a result of the Merger, the existing awards of restricted stock units in respect of Akoya common stock and of options to acquire Akoya common stock will be automatically converted into equivalent awards with respect to shares of Common Stock of the Issuer, subject to the same vesting schedule and other terms and conditions as existed prior to such conversion. The conversion of such equity awards (including, in the case of stock options, the exercise price thereof) will be based on the Exchange Ratio. However, equity awards that, by their existing terms, provide for vesting acceleration triggered in connection with the Merger will be so accelerated in accordance with such terms. Upon completion of the Merger, the Issuer stockholders will own approximately 70%, and Akoya stockholders will own approximately 30%, of the shares of Common Stock of the Issuer on a fully diluted basis. Pursuant to the terms of the Merger Agreement, as of the Effective Time, the Board of Directors of the Issuer will consist of 9 individuals, including seven existing directors of the Issuer and two individuals to be nominated by Akoya prior to the Effective Time.

Item 4. Purpose of Transaction

The information contained in Item 3 of this Schedule 13D is incorporated by reference herein. The Merger Agreement, and the transactions contemplated thereby, if consummated, would relate to or result in one or more of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, including, without limitation, a merger or other extraordinary transaction involving the Issuer and a change in the present Board of Directors of the Issuer. Except as set forth or incorporated by reference in this Schedule 13D, Akoya does not have any plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. This Schedule 13D and the Schedule hereto shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the proposed Merger, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. In connection with the Merger, Quanterix will file with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 (the "registration statement"), which will contain a joint proxy statement of Quanterix and Akoya and a prospectus of Quanterix (the "joint proxy statement/prospectus"), and each of Quanterix and Akoya may file with the SEC other relevant documents regarding the Merger. **INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE JOINT PROXY STATEMENT/PROSPECTUS CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BY QUANTERIX AND AKOYA, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT QUANTERIX, AKOYA AND THE MERGER.** A definitive copy of the joint proxy statement/prospectus will be mailed to Quanterix and Akoya stockholders when that document is final. Investors and security holders will be able to obtain the registration statement and the joint proxy statement/prospectus, as well as other filings containing information about Quanterix and Akoya, free of charge from Quanterix or Akoya or from the SEC's website when they are filed. The documents filed by Quanterix with the SEC may be obtained free of charge at Quanterix's website, at [www.quanterix.com](http://www.quanterix.com), or by requesting them by mail at Quanterix Investor Relations, 900 Middlesex Turnpike, Billerica, MA 01821. The documents filed by Akoya with the SEC may be obtained free of charge at Akoya's website, at [www.akoyabio.com](http://www.akoyabio.com), or by requesting them by mail at Akoya Biosciences, 100 Campus Drive, 6th Floor, Marlborough, MA 01752, Attn: Chief Legal Officer.

Item 5. Interest in Securities of the Issuer

(a) 2,955,532 shares representing 6.2% of the outstanding shares of Common Stock

(b) Other than those shares of Common Stock that may be deemed to be beneficially owned by operation of the Voting

Agreement, the Reporting Person does not beneficially own any shares of Common Stock. For purposes of Rule 13d-3 under the Exchange Act, the Reporting Person may be deemed to have (i) sole power to vote or direct the vote of 0 shares of Common Stock; (ii) shared power to vote or direct the vote of 2,955,532 shares of Common Stock; (iii) sole power to dispose or direct the disposition of 0 shares of Common Stock; and (iv) shared power to dispose or direct the disposition of 0 shares of Common Stock

(c) The Reporting Person has not effected any transaction in the Common Stock of the Issuer during the past sixty day and, to the knowledge of the Reporting Person, none of the persons listed on Schedule A have effected any such transaction

(d) Other than the Supporting Stockholders, to the knowledge of the Reporting Person, no person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of Common Stock of the Issuer beneficially owned by the Reporting Person as described in this Item 5.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 3 above summarizes the provisions of the Voting Agreement, the Merger Agreement and the Lock-Up Agreements and is incorporated by reference herein. The foregoing descriptions of the Voting Agreement and the Merger Agreement are qualified in their entirety by reference to the full text of such agreements, copies of which are filed hereto as Exhibits 99.2 and 99.3, respectively, and are incorporated by reference in their entirety herein.

Item 7. Material to be Filed as Exhibits.

99.1 Schedule A 99.2 Form of Voting and Support Agreement (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the SEC on January 10, 2025 by Akoya Biosciences, Inc.) 99.3 Agreement and Plan of Merger, dated as of January 9, 2025, by and among Quanterix Corporation, Wellfleet Merger Sub, Inc. and Akoya Biosciences, Inc. (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed with the SEC on January 10, 2025 by Akoya Biosciences, Inc.)

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Akoya Biosciences, Inc.

Signature: /s/ Brian McKelligon

Name/Title: Brian McKelligon, Chief Executive Officer

Date: 01/16/2025

**SCHEDULE A****Directors and Executive Officers of Akoya Biosciences, Inc.**

<b>Name</b>	<b>Position</b>
Brian McKelligon	President, Chief Executive Officer and Director
Johnny Elk	Chief Financial Officer
Jennifer Kamocsay	General Counsel
Pascal Bamford	Chief Clinical Officer
Niro Ramachandran	Chief Business Officer
Robert G. Shepler	Director, Chairman of the Board
Thomas Raffin	Director
Thomas P. Schnettler	Director
Scott Mendel	Director
Matthew Winkler	Director
Myla Lai-Goldman	Director

---